Falcarindiol, an orally active polyacetylenic oxylipin, activates PPARγ and increases the expression of the cholesterol transporter ABCA1 in cells. Falcarindiol induces apoptosis and autophagy . Falcarindiol has anti-inflammatory, antifungal, anticancer and antidiabetic properties In Vitro Falcarindiol (3, 6, 12, 24 µM; for 24 hours) significantly decreases cell viability of MDA-MB-231 and MDA-MB-468 cells. Cell viability of MCF-10A cells is unchanged until the dose of Falcarindiol reaches to 24 uM. Falcarindiol preferentially induces cell death in breast cancer cells. Falcarindiol (6 uM; for 2 hours) induces autophagy and causes significant level of LC3-I converted to LC3-II in MDA-MB-231, MDA-MB-468 and SKBR3 cells. Falcarindiol (6 uM; for 2, 4, 8, 24 hours) increases the level of GRP78 in MDA-MB-231 cells in dose- and time-dependent manner. Falcarindiol (1-20 µM) has no effect on hMSCs and HT-29 cell viability. Falcarindiol with only concentrations above 50 µM exhibits a toxic effect on the cells. Falcarindiol (5 µM; 10 min, 1 h and 24 h) causes a significant upregulation on PPARγ2 expression at 24 h. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Falcarindiol (7 µg/g; diet) increases ABCA1 expression in neoplastic tissue in five weeks old male rats. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Oil IC50& Target:PPARγ